Uncategorized
Genomics initiative could boost AI-designed therapeutics

A new initiative is set to generate and model biological data at the trillion-gene scale, paving the way to scale AI-designed therapeutics.
The Trillion Gene Atlas, developed by Basecamp Research in collaboration with Anthropic, Ultima Genomics, PacBio, and NVIDIA AI infrastructure aims to expand known evolutionary genetic diversity 100-fold by collecting genomic data from more than 100 million species across thousands of sites worldwide.
The initiative, unveiled during the Health Track at SXSW and the NVIDIA GTC conference in San Jose, could help drive AI drug development and therapeutic design.
“Today’s biological AI models are trained on a narrow slice of life on Earth,” said Glen Gowers, Co-Founder and CEO of Basecamp Research, speaking at SXSW in Austin.
“The Trillion Gene Atlas expands the known genetic universe by orders of magnitude beyond what is in public databases. Training models at this scale establishes a new paradigm for programmable therapeutic design.”
Trillion Gene Atlas to expand genomics data
With huge increases in model size and computing power, diverse data is a critical enabler for progress in AI drug development and real-world benchmarks.
All current sequence-based foundation models rely on variants of the same public repositories, with 80% of these trained on a public database containing fewer than 250 million sequences.
Basecamp Research’s EDEN foundation models, released in January, bypass the industry’s evolutionary “data wall” by training entirely on BaseData, a proprietary genomic database that is currently more than 10 times larger than all public resources combined. By learning from an unprecedented 10 billion new-to-science genes across one1 million newly discovered species, EDEN unlocked critical new scaling laws for AI in biology.
The Trillion Gene Atlas builds on this approach by greatly expanding the breadth and contextual depth of genomic data in the known “internet of biology” suitable for AI training.
The tool is enabled by advances in ultra-high-throughput short- and long-read sequencing and accelerated computing. Basecamp has partnered with Ultima Genomics and PacBio to deliver industrial-scale sequencing including data-rich, high-accuracy long reads.
“PacBio HiFi sequencing delivers highly accurate long reads that preserve full genomic context and enables subspecies and even strain-level resolution in complex samples,” said Christian Henry, President and CEO of PacBio.
“HiFi data provides the reliable, information-rich foundation biological AI models need to learn from nature at scale and power initiatives like the Trillion Gene Atlas.”
“Biology has been fundamentally data-starved when compared to other fields like language or computer vision as researchers have lacked the tools required to generate data at scale,” added Gilad Almogy, Founder and CEO of Ultima Genomics.
“We strongly believe that AI will have an immense impact on our understanding of biology and human health, and the UG200 Series was designed from the ground up to enable the massive datasets required for BioAI to deliver on this promise. We are excited our technology can enable Basecamp in their vision and advance innovative initiatives like the Trillion Gene Atlas.”
The post Genomics initiative could boost AI-designed therapeutics appeared first on Drug Discovery World (DDW).
Uncategorized
BioNTech to shutter Singapore HQ after ‘comprehensive review’
BioNTech, in a move to streamline its operations, is set to close its factory in Singapore that it bought from Novartis just over three years ago.
The facility at the Tuas Biomedical Park, which employs …
Uncategorized
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.
The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to ClinicalTrials.gov.
Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.
The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to ClinicalTrials.gov.
Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.
Uncategorized
Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI
About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians.
Only a fraction of the people in that room were clinicians.
That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate.
About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians.
Only a fraction of the people in that room were clinicians.
That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors